Adam C. Vandervoort's departure as Chief Legal Officer of Teladoc Health, Inc. was reported, effective November 1, 2026; the filing names no successor. As of November 6, 2026, Teladoc Health, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from March 30, 2026 to September 25, 2026, naming 3 appointments and 1 departure (Form 8-K, September 25, 2026).
Teladoc Health, Inc. announced the departure of its Chief Legal Officer on Sep 25. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Teladoc Health, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Out · Person: Adam C. Vandervoort · Role: Chief Legal Officer · Effective: 2026-11-01 · 8-K, 2026-09-25
- · In / out: In · Person: Michael Grasher · Role: Chief Financial Officer · Effective: 2026-08-31 · 8-K, 2026-08-31
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-08-13
- · In / out: In · Person: Mark V. Anquillare · Role: Director · Effective: 2026-08-03 · 8-K, 2026-08-03
- · In / out: In · Person: Susan R. Salka · Role: Director · Effective: 2026-03-30 · 8-K, 2026-03-30
Teladoc Health, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-03-30 to 2026-09-25. They name 4 people, with 3 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Teladoc Health, Inc. files it.
Also on the record for Teladoc Health, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 8, 2026 | Stake report, Schedule 13G, by Dimensional Fund Advisors LP | 5% of the class | 5%+ stakes | Source |
| June 22, 2026 | Stake report, Schedule 13G, by Voss Capital, LP | 5% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.16% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 6.97% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Point72 Asset Management, L.P. | 3.3% of the class | 5%+ stakes | Source |
| July 29, 2025 | Stake report, Schedule 13G/A, by The Vanguard Group | 11.98% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Teladoc Health, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Teladoc Health, Inc. and the records around it.
Teladoc Health, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Voss Value Master Fund, LP also filed stake reports on 13 other companies: Five9, Inc. (Oct 2026), Cellebrite DI Ltd. (Aug 2026), ALTA EQUIPMENT GROUP INC. (Jul 2026)
- Point72 Asset Management, L.P. also filed stake reports on 90 other companies: Immunocore Holdings plc (Nov 2026), Target Hospitality Corp. (Nov 2026), E.W. SCRIPPS Co (Oct 2026)
- Dimensional Fund Advisors LP also filed stake reports on 366 other companies: Acadia Healthcare Co Inc (Oct 2026), ADT Inc (Oct 2026), AGCO Corp (Oct 2026)
Watch Teladoc Health, Inc.
Get an email when Teladoc Health, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Teladoc Health, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Teladoc Health, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Teladoc Health, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-25 | Out | Chief Legal Officer | 2026-11-01 | 8-K, 2026-09-25 | |
| 2026-08-31 | In | Chief Financial Officer | 2026-08-31 | 8-K, 2026-08-31 | |
| 2026-08-13 | Reported | not named in the filing | 8-K, 2026-08-13 | ||
| 2026-08-03 | In | Director | 2026-08-03 | 8-K, 2026-08-03 | |
| 2026-03-30 | In | Director | 2026-03-30 | 8-K, 2026-03-30 |
Who leads Teladoc Health, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Legal Officer: Adam C. Vandervoort, departure reported, effective 2026-11-01 (filed 2026-09-25). No successor is named in these filings.
- Chief Financial Officer: Michael Grasher, appointed, effective 2026-08-31 (filed 2026-08-31).
- Director: Mark V. Anquillare, appointed, effective 2026-08-03 (filed 2026-08-03).
New leaders reset buying decisions — get the Full Report on Teladoc Health, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Legal Officer at Teladoc Health, Inc., with the record behind each one.
Find candidates like Chief Legal Officer at Teladoc Health, Inc.Every change, in the filing's words
Departing: Adam C. Vandervoort, Chief Legal Officer, effective 2026-11-01
On September 24, 2026, Mr. Adam C. Vandervoort, Chief Legal Officer and Secretary of Teladoc Health, Inc. (the "Company"), informed the Company of his decision to resign, effective November 1, 2026.
- Mr. Vandervoort's resignation was made with good reason under his executive severance agreement with the Company.
- Mr. Vandervoort will provide certain advisory services to the Company, including supporting the transition of his responsibilities as chief legal officer to his successor, until November 1, 2027.
- Mr. Vandervoort will not receive any compensation for his advisory services.
- Following Mr. Vandervoort's departure, Jonathan Dorfman, currently the Company's Senior Vice President, Securities & Corporate Law, will assume the role of Chief Legal Officer and Secretary of the Company.
- The Company thanks Mr. Vandervoort for his years of service.
Appointed: Michael Grasher, Chief Financial Officer, effective 2026-08-31
Effective August 31, 2026, Teladoc Health, Inc. (the "Company") hired Michael Grasher as its Chief Financial Officer.
- Charles Divita, III, who served as the Company's interim principal financial officer, will continue as Chief Executive Officer.
- Prior to joining the Company, Mr. Grasher, age 61, served from February 2024 to September 2025 as Chief Financial Officer of IFG Companies, a privately held multi-line excess and surplus lines insurance company, where he was responsible for financial reporting, planning and analysis, and treasury management.
- Previously, Mr. Grasher served from October 2015 to February 2024 as Chief Financial Officer and Executive Vice President of the Fortegra Group, a global specialty insurer, where he oversaw financial governance and accounting across the company's U.S. and European operations, among other duties.
- Earlier, Mr. Grasher served as Chief Financial Officer and Executive Vice President of AMERISAFE, Inc., a publicly traded workers' compensation insurer, where he led financial reporting, capital management and investor relations.
- Mr. Grasher was also previously an equity research analyst covering insurance companies on both the buy and sell side, and brings a deep understanding of the public markets.
- Mr. Grasher holds a Masters of Business Administration from the University of Chicago Booth School of Business and a Bachelor of Science from the University of Illinois.
Reported
On August 10, 2026, Mr. David B. Snow, Jr. notified Teladoc Health, Inc. (the "Company") of his intention to retire from the Board effective as of September 30, 2026.
- Mr. Snow has been a director of the Company since 2014 and the Company thanks him for his dedicated service.
- Mr. Snow has indicated that he is retiring from the Board for personal reasons and not because of any disagreement with the Company on any matter.
Appointed: Mark V. Anquillare, Director, effective 2026-08-03
Effective August 3, 2026, the Board of Directors (the "Board") of Teladoc Health, Inc. (the "Company") increased the number of directors on the Board to ten and appointed Mark V. Anquillare as a director of the Company.
- Mr. Anquillare was additionally appointed to each of the audit committee and the compensation committee of the Board.
- The Board has determined that Mr. Anquillare is an independent director within the meaning of the New York Stock Exchange listing standards and is an "audit committee financial expert" under Securities and Exchange Commission (the "SEC") and New York Stock Exchange rules.
Appointed: Susan R. Salka, Director, effective 2026-03-30
Effective March 30, 2026, the Board of Directors (the "Board") of Teladoc Health, Inc. (the "Company") increased the number of directors on the Board to nine and appointed Susan R. Salka as a director of the Company.
- Ms. Salka was additionally appointed to each of the audit committee and the compensation committee of the Board.
- The Board has determined that Ms. Salka is an independent director within the meaning of the New York Stock Exchange listing standards and is an "audit committee financial expert" under Securities and Exchange Commission (the "SEC") and New York Stock Exchange rules.
Tools for this story
Each opens in a new tab, filled in for Teladoc Health, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.